Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Edison Investment Research
$10.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Neovacs to present additional data on IFN alpha-Kinoid in SLE treatment


Thursday, 15 May 2014 02:04am EDT 

Neovacs SA:To present additional data from phase I/II clinical trial of IFN alpha-Kinoid in treatment of Systemic Lupus Erythematosus (SLE), or lupus, during the European League Against Rheumatism (EULAR)`s Annual European Congress of Rheumatology.Neovacs` first poster "Potent, broad, and specific neutralizing capacities of polyclonal anti-interferon alpha antibodies induced by IFN-Kinoid in SLE patients" shows that polyclonal antibodies induced by immunization with IFN alpha-Kinoid neutralized most IFN alpha subtypes, produced in excess.These results further support superiority of polyclonal antibody strategy over monoclonal antibodies in treatment of SLE.Company`s poster, "Serum IFN-alpha, but not IFN-beta or IFN omega, correlates with IFN signature in SLE patients" further emphasizes role of IFN alpha in the development of SLE.High IFN signature is driven by IFN alpha and is linked to more active form of disease.